$INO INO-4800 Vaccine Description
INO-4800 is a vaccine candidate matched to the novel coronavirus, 2019-nCoV.
Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million. This grant will take Inovio's preclinical and clinical development through Phase 1 human testing of INO-4800.
Inovio's collaborators for this coronavirus vaccine development include the Wistar Institute, VGXI, a fully owned subsidiary of GeneOne Life Science, and Twist Bioscience.
And, on January 30, 2020, Beijing Advaccine Biotechnology announced a collaboration with Inovio Pharmaceuticals, Inc. to advance the development in China of the INO-4800 vaccine candidate, which is targeted against the novel coronavirus named 2019-nCoV.
Inovio's proprietary platform is leading the way forward for activation immunotherapy. This one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual's immune system to generate a robust targeted T cell and antibody response.
News 
Market Data 
Discover 
